RA
BMY.RT

Reby Advisors’s Bristol-Myers Squibb Company Contingent Value Rights BMY.RT Stock Holding History

Reby Advisors’s Portfolio BMY.RT Stock Details BMY.RT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		$0 Buy
+150
New +$320 ﹤0.01% 608

Other funds holding BMY.RT

PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
BFS
Bard Financial Services Branford, Connecticut $911M AUM 19.14% 1-Year Est. Return
LGP
Leonard Green & Partners Los Angeles, California $2.77B AUM 3.28% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

Reby Advisors's BMY.RT Position: Q4 2020 in Review

Reby Advisors opened a new position in Bristol-Myers Squibb Company Contingent Value Rights (BMY.RT) in Q4 2020: 150 shares worth $0. The stake represents ﹤0.01% of the portfolio and ranks #608 among its holdings.

546 funds tracked by Wall St. Rank hold BMY.RT as of Q4 2020.

  • Reby Advisors held 150 shares of Bristol-Myers Squibb Company Contingent Value Rights worth $0 as of Q4 2020.
  • Bristol-Myers Squibb Company Contingent Value Rights was a new Reby Advisors position in Q4 2020.
  • Bristol-Myers Squibb Company Contingent Value Rights made up ﹤0.01% of Reby Advisors's portfolio in Q4 2020, its #608 holding.
  • 546 funds tracked by Wall St. Rank held Bristol-Myers Squibb Company Contingent Value Rights as of Q4 2020.

Based on Reby Advisors's 13F filing for Q4 2020, filed 12 Feb 2021.